Dual non-viral gene delivery from microparticles within 3D high-density stem cell constructs for enhanced bone tissue...

Area of Science:

• Biomaterials Science
• Stem Cell Biology
• Tissue Engineering

Background:

• Mesenchymal stem cells (MSCs) can form bone-like tissue via endochondral ossification.
• Controlled delivery of growth factors (GFs) like TGF-β1 and BMP-2 can guide MSC differentiation.
• Protein-based GFs have stability issues, making localized gene delivery an attractive alternative.

Purpose of the Study:

• To investigate the efficacy of localized gene delivery of TGF-β1 and BMP-2 using mineral-coated hydroxyapatite microparticles (MCM) within MSC aggregates.
• To assess the potential of this non-viral gene therapy approach to induce osteogenesis and overcome GF stability limitations.
• To evaluate donor-to-donor variability in MSC response to gene delivery for bone regeneration.

Main Methods:

• Mineral-coated hydroxyapatite microparticles (MCM) were loaded with plasmid DNA (pDNA) encoding for TGF-β1 (pTGF-β1) and BMP-2 (pBMP-2).
• These MCM-pDNA nanocomplexes were incorporated into high-density MSC aggregates from three porcine donors.
• MSC aggregates were cultured and analyzed for chondrogenesis (glycosaminoglycan production) and osteogenesis at weeks 2 and 4.

Main Results:

• Delivery of pBMP-2 in Donor 1 MSC aggregates promoted chondrogenesis and enhanced osteogenesis.
• Donors 2 and 3 showed varied responses, with combined pTGF-β1/pBMP-2 or pBMP-2 delivery enhancing osteogenesis by week 4.
• Results demonstrate successful induction of osteogenesis through localized, non-viral gene delivery in MSC aggregates.

Conclusions:

• Localized gene delivery within MSC aggregates is a viable strategy for promoting osteogenesis.
• Donor variability in MSC differentiation capacity necessitates pre-clinical screening for gene therapy applications.
• This gene therapy approach shows promise for treating bone defects by controlling stem cell fate in 3D cultures.